Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: yosid who wrote (1716)	3/6/2000 5:29:00 PM
From: Thai Chung	Read Replies (1) \| Respond to of 1754

biz.yahoo.com Business Wire NOTICE ISSUED BY INTERNATIONAL TRADE COMMISSION BUSINESS EDITORS, HEALTH/MEDICAL WRITERS SANTA CLARA, Calif.--(BW HealthWire)--March 6, 2000--VISX, INCORPORATED (NASDAQ: VISX.O) today announced that the United States International Trade Commission (ITC) has issued a Notice of its decision in the investigation of the activities of Nidek Co. Ltd. and its United States subsidiaries. The Commission adopted portions of the Initial Determination of the ITC issued in December 1999, ruling that Nidek and its United States subsidiaries have not violated Section 337 of the Tariff Act of 1930, as amended on the basis that the Nidek laser system does not infringe the VISX's United States Patent No. 5,711,762 and that VISX does not practice that patent. With regard to the validity and enforceability of the patent, the Commission did not affirm the Initial Determination and took no position. The Commission did not review the findings of the ITC administrative law judge with respect to VISX's U.S. Patent Number 4,718,418. That ruling upholding the enforceability of the `418 Patent but finding that it was not infringed by the Nidek System is therefore final. The Commission's determination is subject to review by the United States Court of Appeals for the Federal Circuit and VISX may appeal all or a portion of the decision. VISX is a worldwide leader in the development of refractive laser technology. VISX systems are commercially available in the United States and markets worldwide. --30--ap/sf* CONTACT: VISX Inc. Lola Wood, 877/463-6847 ir@visx.com visx.com KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL DEVICES Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 2000, Business Wire What's next? Long on VISX. Good Luck to all.

To: yosid who wrote (1716)	3/6/2000 9:33:00 PM
From: jelrod3	Read Replies (1) \| Respond to of 1754

Pretty good call... daytraders and/or buyers boosted the price in pre-market trading, and as the day wore on, pulled the plug and sold. Now, with the ITC announcement out, what do you think will happen tomorrow? And beyond tomorrow? I have been looking at the whole "laser vision correction" industry. Am I missing something, or is it true that the real money will be made by the laser vision correction centers, like LCAV and LVCI, who will offer this "soon to be a commodity product" to the public at falling prices? Looks like some 160 million people are afflicted with nearsightedness/farsightedness, and that about 60 million people can afford the procedure in the $1000 to $3000 range for both eyes. So far, about 1.2 to 2.0 million have had the procedure, so the market is far from being penetrated. Admittedly, more lasers will be built and sold, and more license fees paid to companies like VISX, but WHO is really going to make the money profit margin wise? The service providers, or the laser makers?